glp-1 natural agonist The Next Wave of Obesity Treatment: Oral Medications GLP-1 and Dual GIP/GLP-1 Agonists

References Bhm, M

This is due to the rapidly rising prevalence of diabetes and obesity across major economies

Monitoring and assessment Regardless of protocol, regular monitoring should include: Cognitive testing at baseline and regular intervals (MMSE, MoCA, or ADAS-cog) Vital signs during and after each administration session Hepatic and renal function panels (baseline and periodic) Neurological examination for seizure risk assessment Self-reported side effects diary Track progress using standardized scales

The difficulty of conducting imaging studies in OUD individuals during acute opioid withdrawal did not allow us to expand the sample size